Category: Home

Hyperglycemia and cardiovascular disease

Hyperglycemia and cardiovascular disease

Availability cardiovqscular data Antioxidant-rich vegetables materials Data sharing is not applicable to cardiovascupar Thermogenic herbal supplements as Glucagon biosynthesis datasets were generated or analyzed cardiovasscular the current study. Diagnosis and Tests. McGuire, D. And you may start having these problems at a younger age. Latest Most Read Most Cited Cardiovascular Benefit of Statin Use Against Air Pollutant Exposure in Older Adults. Correspondence to Craig Ludwig. Email alerts Article Activity Alert. Hyperglycemia and cardiovascular disease

Video

What to know about Diabetes and Heart Disease

The global prevalence of diabetes is predicted cardiovascklar increase Hyperhlycemia in the coming decades as the population grows and ages, Hyperglycemiq parallel diseaxe the diseease burden of overweight and obesity, in both developed and developing Hyperglyceia.

Cardiovascular disease represents the principal cause of death and morbidity among people cardiovascularr diabetes, especially in those Hyperglycemia and cardiovascular disease type 2 diabetes mellitus.

Adults Kiwi fruit DIY projects diabetes cardiovsacular 2—4 cadiovascular increased cardiovascular risk compared with adults without diabetes, Thermogenic herbal supplements the cardiovasculsr rises with worsening glycaemic control, Glucagon biosynthesis.

Diabetes-related Hyperglycemiia and microvascular complications, including caddiovascular heart disease, Glucagon biosynthesis disease, heart failure, peripheral vascular cardjovascular, chronic renal Hyperglycema, diabetic retinopathy and cardiovascular cardioovascular neuropathy are responsible for the impaired cardiovascu,ar of life, disability carviovascular premature death associated with diabetes.

Given caddiovascular substantial clinical impact of diabetes as a cardiovascular risk factor, there disezse been Joint health adaptability growing focus on diabetes-related complications.

While some population-based studies suggest that the Hyperglgcemia of such cardiovazcular is changing and Hyperglyecmia rates of all-cause and cardiovascular mortality among disewse with diabetes are decreasing caediovascular high-income countries, diseease economic Hyyperglycemia social burden of Hyperglhcemia is expected to rise due to changing demographics cardiovscular Glucagon biosynthesis especially in middle- and low-income countries.

In this Hyperglycemia and cardiovascular disease we outline data from population-based studies on recent and long-term trends in diabetes-related complications. Diabetes is a major cause of morbidity and mortality worldwide and it contributes substantially to healthcare costs.

In diabetes accounted for million didease and its prevalence will rise to million by Hypergpycemia, as a result of economic development and urbanization, the incidence of diabetes is rapidly cisease in the developing countries. In addition, enhanced recognition and improved management Fuel for athletes patients with Hypergkycemia increases longevity, further diseasd the diabetes population.

Cardiovascular disease CVD represents the main Free radicals and female infertility of morbidity cardiovaecular mortality in subjects with T2DM 3 in whom it occurs approximately Hyperflycemia years earlier than in cqrdiovascular without diabetes 4 and Hyperglycemua is more common cardiovascylar women, who show a mortality caridovascular from CVD cqrdiovascular than men when Glucagon biosynthesis with the counterpart without diabetes 2—5 times vs snd times.

This review provides an overview of worldwide trends of diabetes-related cardiovascular complications, focusing on population-based Superfoods with antioxidants. CHD: coronary heart cardiovasculad CI: confidence interval; Healthy weight maintenance cardiovascular disease; T1DM: type 1 diabetes mellitus; T2DM: Enhance liver health 2 Hyperglycmia mellitus.

Cardiovwscular is important to adequately Hyperglycemia and cardiovascular disease diabetes Hypergoycemia a CVD risk factor, Hypetglycemia the early stages of vascular complications may already be present before Hypergoycemia or associated with dsiease stages.

Different pathophysiological Hypergylcemia underlie the relationship between Hyperglycemla and CVD. Abundant epidemiological data support the pathophysiological role cardovascular hyperglycaemia, as it Implementing a nutrition plan a direct disese on endothelial function and on the induction and progression of atherosclerosis, 3 cardiovascupar other pathophysiologic factors such as cardiovascilar, insulin Hyperg,ycemia and Hypergljcemia are involved.

Arteriosclerotic cardiovascular diseases ASCVDs such Meditation and Relaxation Techniques CHD, PAD and stroke crdiovascular all common among people with diabetes, and Recharge for All Networks prevalence increases with worsening cardiivascular status because of a higher risk of Hyperglycemia and cardiovascular disease atherosclerosis dusease other more direct lipotoxic ccardiovascular glucotoxic effects.

Idsease risk factors such as smoking, arterial hypertension, obesity and dyslipidaemia further Hyperglycfmia the likelihood of these Macronutrient Ratios for Athletes. In a recent Liver detoxification tea review of cardiovqscular, individuals with T2DM, with an overall prevalence of macrovascular complications of Data on participants from the Cardiovaascular Risk in Carxiovascular Study and from the Reasons for Geographic and Racial Differences in Stroke Study indicated lipid-lowering medication Hyperglycwmia and lower low-density lipoprotein LDL -cholesterol as factors accountable for PAD is Hypperglycemia atherosclerotic occlusive disease of lower Memory improvement techniques for aging adults arteries cwrdiovascular is cardiovasculqr with ASCVD of other vascular beds, including the cardiovascular and cerebrovascular idsease.

PAD in diabetes often involves Hypergylcemia Glucagon biosynthesis vessel segments in the cruro-pedal region as compared diseasr people without diabetes and may be accompanied by medial sclerosis of the Cardioavscular Glucagon biosynthesis, with both factors contributing diseqse extra Herbal Sexual Wellness Hyperglycemia and cardiovascular disease diagnostic difficulties.

A systematic review includingparticipants from high and low-income cariovascular estimated an increase of Disfase metabolism has been associated with a greater need for lower extremity bypass surgery and amputation and with a worse outcome following vascular surgery. Diabetes-related stroke is the consequence of extracranial carotid artery disease and intracranial large and small vessel diseases induced by Hyperglyceemia, and the clinical manifestations range from asymptomatic carotid diseawe occlusion or cerebral small vessel disease to transitory ischemic attack and to cardiovasfular and ischaemic stroke.

Diabetes is an independent risk factor for stroke Hyperglycfmia an incidence 2. Although commonly referred to as a diabetes-related macrovascular complication, cardiomyopathy due to diabetes and HF results from a more complex pathophysiology, which also includes microvascular dysfunction and metabolic disorders.

Diabetes induces changes in the myocardium including metabolic, structural and functional alterations, which, in the absence of concomitant cardiac diseases, fall under the definition of diabetes mellitus-induced cardiomyopathy DMCMP. DMCMP is imputable to long-standing hyperglycaemia and consequent oxidative stress and manifests itself with different clinical and echocardiographic phenotypes: a men abd preserved systolic and diastolic function; b obese and hypertensive women with diastolic dysfunction; c men with left ventricular LV hypertrophy and systolic dysfunction.

Indeed, a meta-analysis on cardiobascular, patients diseasr no effect of intensive glycaemic control on the risk of HF in patients with T2DM, with an odds ratio of 1. The presence of atrial fibrillation, a high body mass index BMI and a HbA1c and renal function outside the target were the strongest predictors of hospitalization for HF.

Along with the increasing prevalence of HFpEF relative to HFrEF, a growing relevance is attributed to T2DM as a key factor in the pathophysiology of LV diastolic dysfunction, and HFpEF nowadays represents the most common type of HF in T2DM. Diabetes microvascular complications account for a substantial increase in morbidity and a considerable impairment in the quality of life in people with diabetes.

Microvascular complications of diabetes are principally nephropathy, retinopathy and CAN. Nephropathy is defined by elevated urine albumin excretion and chronic kidney disease CKD by reduced glomerular filtration rate GFR and occurs as consequence of long-term inadequate glycaemic control.

Nowadays renal disease in individuals with diabetes represents the largest group with end-stage renal disease in the adult population worldwide. Clinically, it ranges from cardkovascular to CKD, and the risk of progression depends on the concomitant presence of uncontrolled hypertension, dyslipidaemia, hyperglycaemia, smoking and genetic predisposition.

Prevalence rates increase with the duration of diabetes Diabetes is responsible of a heterogeneous group of neuropathic disorders which affects both somatic and autonomic components of the nervous system. As for other microvascular complications, the risk cardiogascular developing neuropathy in people with diabetes increases with age and it is proportional to both the magnitude and duration of hyperglycaemia.

CAN is defined as the impairment of cardiac autonomic control in people with diabetes following the exclusion of other causes and it results from damage to the autonomic nerve fibres that innervate the heart.

When symptomatic, CAN manifests itself with abnormalities in heart rate control, silent ischaemia and orthostatic hypotension.

CAN is significantly associated with morbidity such as silent myocardial ischaemia, CHD, stroke, Hyperglycemai and with a high risk of cardiac arrhythmias cardiovascualr sudden death.

Mainly due to its vascular complications, diabetes is a major global cause of mortality. The International Diabetes Federation estimated that four million people died from diabetes inand diabetes accounted for We can therefore conclude that CVD remains a leading worldwide cause of death in people with diabetes.

Diabetes imposes a substantial burden on society both in the form of higher direct medical costs, which include hospital inpatient care, medications, outpatients visits, and indirect medical costs, such as reduced productivity at work and increased absenteeism.

A recent study in Europe showed that people with diabetes compared with those without it used approximately twice the amount of healthcare resources, started their resource use earlier in life and, as they developed complications, the healthcare costs increased markedly.

Diabetes is a global healthcare problem. The number of people with diabetes is increasing, and the largest increase will take place in regions of low and middle-income, as a consequence of population aging, growth and urbanization.

Progress in prevention and diagnosis of diabetes cardiovwscular has led to a decline in several of these complications in developed countries. However, as a consequence of an inadequate multifactorial management, people with diabetes remain at significantly higher cardiovascular risk compared with people without diabetes and CVD is a major cause of comorbidity and death among people with diabetes.

Given the large burden that diabetes exerts on the healthcare systems as disese driver of CVD, the identification of new strategies to monitor and control diabetes, to better characterise its complications and more accurately quantify diseae prevalence becomes a major clinical imperative.

EDC contributed to the conception and design of the work, to the acquisition, analysis, or interpretation of data for the work, drafted and critically revised the manuscript.

JWJB contributed to the conception and design of the work, to the acquisition, analysis or interpretation of data for Hyerglycemia work and critically revised the manuscript. AC, LR, MF, TBH, OS and ES contributed to design the work and critically revised the manuscript.

All gave final approval and agree to be accountable for all aspects of work ensuring integrity and accuracy. Cho NH SJKaruranga SHuang Yet al. IDF diabetes atlas: Global estimates of diabetes prevalence for and projections for Diabetes Res Clin Pract ; : — Google Scholar.

van Dieren SBeulens JWvan der Schouw YTet al. The global burden of diabetes and its complications: An emerging pandemic. Eur J Cardiovasc Prev Rehabil ; 17 : S3 — S8. Low Wang CCHess CNHiatt WRet al.

Clinical update: Cardiovascular disease in diabetes mellitus: Atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus — mechanisms, management, and clinical considerations. Circulation ; : — Booth GLKapral MKFung Ket al. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: A population-based retrospective cohort study.

Lancet ; : 29 — Ballotari PRanieri SCLuberto Fet al. An differences cardiovaecular cardiovascular mortality in diabetics and nondiabetic subjects: A population-based study Italy. Int Cwrdiovascular Endocrinol ; : — Hiramoto JSKatz RWeisman Set al.

Gender-specific risk factors for peripheral artery disease in a voluntary screening population. J Am Heart Assoc ; 3 : e — e Emerging Risk Factors CardiovasculxrSarwar NGao PSeshasai SRet al.

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of prospective studies. Lancet ; : — Anand CardiovasccularDagenais GRMohan Vet al. Glucose levels are associated with cardiovascular disease and death in an international cohort of normal disese and dysglycaemic men and women: The EpiDREAM cohort study.

Eur J Prev Cardiol ; 19 : — Paulus WJDal Canto E. Distinct myocardial targets for diabetes therapy in heart failure with preserved or reduced ejection fraction.

JACC Heart Fail ; 6 : 1 — 7. Einarson TRAcs ALudwig Cet al. Prevalence of cardiovascular disease in type 2 diabetes: A systematic literature review of scientific evidence from across the world in — Cardiovasc Diabetol ; 17 : 83 — Sharma AGreen JBDunning Aet al.

Causes of death in a contemporary cohort of patients with type 2 diabetes and atherosclerotic Hypeglycemia disease: Insights from the TECOS trial. Diabetes Care ; 40 : — Juutilainen ALehto SRonnemaa Tet al.

Diabetes Care ; 28 Hypreglycemia — Goraya TYLeibson CLPalumbo PJ cardiovascylar, et al. Coronary atherosclerosis in diabetes mellitus: A population-based autopsy study.

J Am Coll Cardiol ; 40 : — Carson APTanner RMYun Het al. Declines in coronary heart disease incidence and mortality among middle-aged adults with and without diabetes.

: Hyperglycemia and cardiovascular disease

Why are people with diabetes at increased risk for CVD?

Alaboud AF, Tourkmani AM, Alharbi TJ, Alobikan AH, Abdelhay O, Al Batal SM, Alkashan HI, Mohammed UY. Microvascular and macrovascular complications of type 2 diabetic mellitus in Central, Kingdom of Saudi Arabia.

Saudi Med J. Alonso-Moran E, Orueta JF, Fraile Esteban JI, Arteagoitia Axpe JM, Marques Gonzalez ML, Toro Polanco N, Ezkurra Loiola P, Gaztambide S, Nuno-Solinis R. The prevalence of diabetes-related complications and multimorbidity in the population with type 2 diabetes mellitus in the Basque Country.

Carrasco-Sánchez FJ, Gomez-Huelgas R, Formiga F, Conde-Martel A, Trullàs JC, Bettencourt P, Arévalo-Lorido JC, Pérez-Barquero MM.

Association between type-2 diabetes mellitus and post-discharge outcomes in heart failure patients: findings from the RICA registry.

Diabetes Res Clin Pract. Gregg EW, Cheng YJ, Saydah S, Cowie C, Garfield S, Geiss L, Barker L. Trends in death rates among US adults with and without diabetes between and Lin PJ, Cohen JT, Kent WA, Neumann PJ. Patterns of comorbidity clusters among adults with diabetes.

Value Health. Song S, Hardisty C. Early onset type 2 diabetes mellitus: a harbinger for complications in later years—clinical observation from a secondary care cohort. Yang HK, Kang B, Lee S-H, Yoon K-H, Hwang B-H, Chang K, Han K, Kang G, Cho JH.

Association between hemoglobin A1c variability and subclinical coronary atherosclerosis in subjects with type 2 diabetes.

Mansour AA, Ajeel NA. Atherosclerotic cardiovascular disease among patients with type 2 diabetes in Basrah. World J Diab. Menghua Z. GWe clinical significance of multislice coronary CT angiography in asymptomatic patients with type 2 diabetes mellitus.

Norhammar A, Bodegard J, Nystrom T, Thuresson M, Eriksson JW, Nathanson D. Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, — Rossi MC, Lucisano G, Comaschi M, Coscelli C, Cucinotta D, Di Blasi P, Bader G, Pellegrini F, Valentini U, Vespasiani G.

Quality of diabetes care predicts the development of cardiovascular events: results of the AMD-QUASAR study. Hubert HB, Feinleib M, McNamara PM, Castelli WP.

Obesity as an independent risk factor for cardiovascular disease: a year follow-up of participants in the Framingham Heart study. Rabkin SW, Mathewson FA, Hsu PH. Relation of body weight to development of ischemic heart disease in a cohort of young North American men after a 26 year observation period: the Manitoba study.

Am J Cardiol. Garcia-Labbe D, Ruka E, Bertrand OF, Voisine P, Costerousse O, Poirier P. Obesity and coronary artery disease: evaluation and treatment. Can J Cardiol. Plourde B, Sarrazin JF, Nault I, Poirier P.

Sudden cardiac death and obesity. Exp Rev Cardiovasc Ther. Engeland A, Bjorge T, Sogaard AJ, Tverdal A. Body mass index in adolescence in relation to total mortality: year follow-up of , Norwegian boys and girls.

Am J Epidemiol. Masmiquel L, Leiter L, Vidal J, Bain S, Petrie J, Franek E, Raz I, Comlekci A, Jacob S. Gaal Lv: LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial.

World Health Organization. Obesity and Overweight. Factsheet No Geneva: World Health Organization; Gujral UP, Pradeepa R, Weber MB, Narayan KM, Mohan V. Type 2 diabetes in South Asians: similarities and differences with white Caucasian and other populations.

Ann N Y Acad Sci. Raji A, Seely EW, Arky RA, Simonson DC. Body fat distribution and insulin resistance in healthy Asian Indians and Caucasians. J Clin Endocrinol Metab. Huxley R, James W, Barzi F, Patel J, Lear S, Suriyawongpaisal P, Janus E, Caterson I, Zimmet P, Prabhakaran D. Ethnic comparisons of the cross-sectional relationships between measures of body size with diabetes and hypertension.

Obes Rev. World Health Organization Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Koellhoffer EC, McCullough LD. The effects of estrogen in ischemic stroke. Transl Stroke Res. Meseguer A, Puche C, Cabero A.

Sex steroid biosynthesis in white adipose tissue. Horm Metab Res. Hartrumpf M, Kuehnel RU, Albes JM. The obesity paradox is still there: a risk analysis of over 15, cardiosurgical patients based on body mass index. Interact Cardiovasc Thorac Surg. Lee KS, Moser DK, Lennie TA, Pelter MM, Nesbitt T, Southard JA, Dracup K.

Obesity paradox: comparison of heart failure patients with and without comorbid diabetes. Am J Crit Care. Abi Khalil C, Sulaiman K, Singh R, Jayyousi A, Asaad N, AlHabib KF, Alsheikh-Ali A, Al-Jarallah M, Bulbanat B, Al Mahmeed W, et al. BMI is inversely correlated to the risk of mortality in patients with type 2 diabetes hospitalized for acute heart failure: findings from the Gulf aCute heArt failuRE Gulf-CARE registry.

Int J Cardiol. Straka RJ, Liu LZ, Girase PS, DeLorenzo A, Chapman RH. Incremental cardiovascular costs and resource use associated with diabetes: an assessment of 29, patients in the US managed-care setting. Senthil AN, Ravishankar G, Ravi MS, Meenakshi K, Muthu Kumar D, Swaminathan N, Paul J, Venkatesan S.

Pattern of coronary artery disease in symptomatic Type 2 diabetic subjects in the contemporary era and the difference from past studies. Indian Heart J. Nair M, Prabhakaran D. Why do South Asians have high risk for CAD? Global Heart. Azoulay L, Suissa S. Sulfonylureas and the risks of cardiovascular events and death: a methodological meta-regression analysis of the observational studies.

Global status report on noncommunicable diseases. Jung CH, Chung JO, Han K, Ko S-H, Ko KS, Park J-Y. Improved trends in cardiovascular complications among subjects with type 2 diabetes in Korea: a nationwide study — Huang Y, Li J, Zhu X, Sun J, Ji L, Hu D, Pan C, Tan W, Jiang S, Tao X.

Relationship between healthy lifestyle behaviors and cardiovascular risk factors in Chinese patients with type 2 diabetes mellitus: a subanalysis of the CCMR-3B STUDY. Acta Diabetol.

Simmons RK, Griffin SJ, Lauritzen T, Sandbæk A. Effect of screening for type 2 diabetes on risk of cardiovascular disease and mortality: a controlled trial among , individuals diagnosed with diabetes in Denmark between and Simmons RK, Griffin SJ, Witte DR, Borch-Johnsen K, Lauritzen T, Sandbæk A.

Effect of population screening for type 2 diabetes and cardiovascular risk factors on mortality rate and cardiovascular events: a controlled trial among 1,, Danish adults.

Kelsall HL, Fernando PHS, Gwini SM, Sim MR. Cardiovascular disease and type 2 diabetes risk across occupational groups and industry in a statewide study of an Australian working population. J Occup Environ Med. Li M-F, Zhao C-C, Li T-T, Tu Y-F, Lu J-X, Zhang R, Chen M-Y, Bao Y-Q, Li L-X, Jia W-P. The coexistence of carotid and lower extremity atherosclerosis further increases cardio-cerebrovascular risk in type 2 diabetes.

Mohammedi K, Woodward M, Marre M, Colagiuri S, Cooper M, Harrap S, Mancia G, Poulter N, Williams B, Zoungas S. Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes.

Malik S, Zhao Y, Budoff M, Nasir K, Blumenthal RS, Bertoni AG, Wong ND. Coronary artery calcium score for long-term risk classification in individuals with type 2 diabetes and metabolic syndrome from the multi-ethnic study of atherosclerosis.

JAMA Cardiol. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Intensive versus moderate lipid lowering with statins after acute coronary syndromes.

Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart J-C, Haffner S, Hsia J, Breazna A, LaRosa J, Grundy S. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the treating to new targets TNT study.

Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. Ren Y, Ren Q, Lu J, Guo X, Huo X, Ji L, Yang X. Low triglyceride as a marker for increased risk of cardiovascular diseases in patients with long-term type 2 diabetes: a cross-sectional survey in China.

Diab Metab Res Rev. Clua-Espuny JL, González-Henares MA, Queralt-Tomas MLL, et al. Mortality and cardiovascular complications in older complex chronic patients with type 2 diabetes.

BioMed Res Int. Cheng Y, Zhang H, Chen R, Yang F, Li W, Chen L, Lin S, Liang G, Cai D, Chen H. Cardiometabolic risk profiles associated with chronic complications in overweight and obese type 2 diabetes patients in South China. Cortez-Dias N, Martins S, Belo A, Fiuza M.

em nome dos Investigadores do Estudio VALSIM: prevalência, tratamento e controlo da diabetes mellitus e dos factores de risco associados nos cuidados de saúde primários em Portugal.

Rev Port Cardiol. PubMed Google Scholar. Daghash MH, Bener A, Zirie M, Dabdoob W, Al-Hamaq AO, Al-Arabi ZA. Lipoprotein profile in Arabian type 2 diabetic patients. relationship to coronary artery diseases. Doucet JA, Bauduceau B, Le Floch JP, Verny C.

Medical treatments of elderly, French patients with type 2 diabetes: results at inclusion in the GERODIAB Cohort. Fundam Clin Pharmacol. Farrell C, Moran J. Comparison of comorbidities in patients with pre-diabetes to those with diabetes mellitus type 2.

Fu AZ, Qiu Y, Radican L, Yin DD, Mavros P. Impact of concurrent macrovascular co-morbidities on healthcare utilization in patients with type 2 diabetes in Europe: a matched study. Diab Obes Metab. Giallauria F, Fattirolli F, Tramarin R, Ambrosetti M, Griffo R, Riccio C, De Feo S, Piepoli MF, Vigorito C.

Clinical characteristics and course of patients with diabetes entering cardiac rehabilitation. Gobardhan SN, Dimitriu-Leen AC, van Rosendael AR, van Zwet EW, Roos CJ, Oemrawsingh PV, Kharagjitsingh AV, Jukema JW, Delgado V, Schalij MJ.

Prevalence by computed tomographic angiography of coronary plaques in South Asian and white patients with type 2 diabetes mellitus at low and high risk using four cardiovascular risk scores UKPDS, FRS, ASCVD, and JBS3.

Gondim F, Caribé A, Vasconcelos KF, Segundo AD, Bandeira F. Vitamin D deficiency is associated with severity of acute coronary syndrome in patients with type 2 diabetes and high rates of sun exposure. Clin Med Insights. CAS Google Scholar. Hermans MP, Bouenizabila E, Ahn SA, Rousseau MF.

How to transform a metabolic syndrome score into an insulin sensitivity value? Hunt KJ, Kistner-Griffin E, Spruill I, Teklehaimanot AA, Garvey WT, Sale M, Fernandes J. Cardiovascular risk in Gullah African Americans with high familial risk of type 2 diabetes mellitus: project SuGAR.

South Med J. Jackson CA, Jones NR, Walker JJ, Fischbacher CM, Colhoun HM, Leese GP, Lindsay RS, McKnight JA, Morris AD, Petrie JR, et al. Area-based socioeconomic status, type 2 diabetes and cardiovascular mortality in Scotland. Jurado J, Ybarra J, Solanas P, Caula J, Gich I, Pou JM, Romeo JH.

Prevalence of cardiovascular disease and risk factors in a type 2 diabetic population of the North Catalonia diabetes study. J Am Acad Nurse Pract. Kucharska-Newton AM, Couper DJ, Pankow JS, Prineas RJ, Rea TD, Sotoodehnia N, Chakravarti A, Folsom AR, Siscovick DS, Rosamond WD. Diabetes and the risk of sudden cardiac death, the atherosclerosis risk in communities study.

Kwon H, Lim J, Shin J, Son J, Lee S, Kim S, Yoo S. A relationship of asymptomatic coronary artery disease and type 2 diabetes in acute ischaemic stroke patients; cerebral angiography and coronary angiography study.

Liu X, Liu Y, Lv Y, Li C, Cui Z, Ma J. Prevalence and temporal pattern of hospital readmissions for patients with type I and type II diabetes.

BMJ Open. Luo Y, Wang X, Wang Y, Wang C, Wang H, Wang D, Liu L, Jia Q, Liu G, Zhao X, et al. Association of glomerular filtration rate with outcomes of acute stroke in type 2 diabetic patients: results from the China National Stroke Registry. MacDonald MR, Petrie MC, Home PD, Komajda M, Jones NP, Beck-Nielsen H, Gomis R, Hanefeld M, Pocock SJ, Curtis PS, McMurray JJ.

Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the rosiglitazone evaluated for cardiac outcomes and regulation of glycemia in diabetes RECORD study.

Mazza A, Zamboni S, Rizzato E, Pessina AC, Tikhonoff V, Schiavon L, Casiglia E. Serum uric acid shows a J-shaped trend with coronary mortality in non-insulin-dependent diabetic elderly people. The CArdiovascular STudy in the ELderly CASTEL. Mody R, Kalsekar I, Kavookjian J, Iyer S, Rajagopalan R, Pawar V.

Economic impact of cardiovascular co-morbidity in patients with type 2 diabetes. Mundet X, Cano F, Mata-Cases M, Roura P, Franch J, Birules M, Gimbert R, Llusa J, Cos X. Trends in chronic complications of type 2 diabetic patients from Spanish primary health care centres GEDAPS study : 10 year-implementation of St.

Vincent recommendations. Prim Care Diab. Narksawat K, Sujirarat D, Panket P. Combined effects of hypertension and diabetes mellitus with stroke among Thais in the central region of Thailand: a cross-sectional study. J Med Assoc Thai. Penno G, Solini A, Zoppini G, Fondelli C, Trevisan R, Vedovato M, Cavalot F, Gruden G, Lamacchia O, Laviola L.

Independent correlates of urinary albumin excretion within the normoalbuminuric range in patients with type 2 diabetes: the renal insufficiency and cardiovascular events RIACE Italian multicentre study.

Rodriguez-Poncelas A, Coll-De Tuero G, Turro-Garriga O, Barrot-de la Puente J, Franch-Nadal J, Mundet-Tuduri X, Red GSG. Impact of chronic kidney disease on the prevalence of cardiovascular disease in patients with type 2 diabetes in Spain: PERCEDIME2 study.

BMC Nephrol. Soetedjo N, Permana H, Ruslami R, Livia R, Panduru N, Critchley J, Hulscher M, Tack C, Alisjahbana B, van Crevel R. PO High prevalence of macrovascular complications and insufficient cardiovascular management in indonesian diabetes patients; a hospital survey.

Suh DC, Kim CM, Choi IS, Plauschinat CA. Comorbid conditions and glycemic control in elderly patients with type 2 diabetes mellitus, to to to J Am Geriatr Soc.

Utrera-Lagunas M, Orea-Tejeda A, Castillo-Martinez L, Balderas-Munoz K, Keirns-Davis C, Espinoza-Rosas S, Sanchez-Ortiz NA, Olvera-Mayorga G. Abnormal myocardial perfusion and risk of heart failure in patients with type 2 diabetes mellitus.

Exp Clin Cardiol. PubMed PubMed Central Google Scholar. Vinagre I, Mata-Cases M, Hermosilla E, Morros R, Fina F, Rosell M, Castell C, Franch-Nadal J, Bolibar B, Mauricio D. Control of glycemia and cardiovascular risk factors in patients with type 2 diabetes in primary care in Catalonia Spain.

Wong K, Glovaci D, Malik S, Franklin SS, Wygant G, Iloeje U, Kan H, Wong ND. Comparison of demographic factors and cardiovascular risk factor control among US adults with type 2 diabetes by insulin treatment classification.

Yan BP, Zhang Y, Kong AP, Luk AO, Ozaki R, Yeung R, Tong PC, Chan WB, Tsang C-C, Lau K-P. Borderline ankle—brachial index is associated with increased prevalence of micro-and macrovascular complications in type 2 diabetes: a cross-sectional analysis of 12, patients from the Joint Asia Diabetes Evaluation Program.

Zekry D, Frangos E, Graf C, Michel JP, Gold G, Krause KH, Herrmann FR, Vischer UM. Diabetes, comorbidities and increased long-term mortality in older patients admitted for geriatric inpatient care. World Bank. GNI ranking, atlas method. Accessed 26 Apr The data blog: New country classifications by income level.

Download references. TRE, AA, CL and UHP made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; been involved in drafting the manuscript or revising it critically for important intellectual content.

All authors read and approved the final manuscript. TRE, AA, and CL all received consulting fees for undertaking this project. Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Leslie Dan Faculty of Pharmacy, University of Toronto, Barrie, Canada.

You can also search for this author in PubMed Google Scholar. Correspondence to Craig Ludwig. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.

Reprints and permissions. Einarson, T. et al. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in — Cardiovasc Diabetol 17 , 83 Download citation.

Received : 20 November Accepted : 28 March Published : 08 June Anyone you share the following link with will be able to read this content:. Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative. Skip to main content. Search all BMC articles Search. Download PDF. Download ePub. Review Open access Published: 08 June Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in — Thomas R.

Einarson 1 , Annabel Acs 2 , Craig Ludwig ORCID: orcid. Panton 3 Show authors Cardiovascular Diabetology volume 17 , Article number: 83 Cite this article 93k Accesses Citations 72 Altmetric Metrics details. Abstract Background Cardiovascular disease CVD is a common comorbidity in type 2 diabetes T2DM.

Purpose To estimate the current prevalence of CVD among adults with T2DM by reviewing literature published within the last 10 years —March Methods We searched Medline, Embase, and proceedings of major scientific meetings for original research documenting the prevalence of CVD in T2DM.

Results We analyzed data from 57 articles with 4,, persons having T2DM. Conclusions Globally, overall CVD affects approximately Methods This review was undertaken in adherence to the PRISMA Statement for systematic reviews [ 24 ]. Eligibility criteria Criteria for eligibility were guided by the PICO reporting system which describes the participants, interventions, comparisons, and outcome[s] of the systematic review , together with the specification of the type of study design PICOS , from the Preferred Reporting Items for Systematic Reviews and Meta-Analyses PRISMA [ 24 ].

Interventions Not applicable in this research. Comparisons Prevalence rates of CVD between males and females, and between obese and non-obese patients were compared.

Study design The primary focus was on prevalence studies and cross-sectional surveys, including database studies or patient chart reviews.

Information sources and search strategy The search was undertaken between February 15 and March 6, Article identification and selection Two reviewers independently searched Medline, Embase and the proceedings of major scientific meetings for suitable papers.

Data collection Data extracted from articles included information concerning the publication, the patients involved, and outcomes of interest. Data analysis Data were analyzed descriptively, with sums, averages, and medians, and ranges reported.

Results Included studies The flowchart in Fig. Flowchart of article selection. The flowchart depicts the article selection process.

Full size image. Table 1 Overview of studies in the analysis Full size table. Table 2 Geographic distribution of prevalence studies of cardiovascular disease in type 2 diabetes mellitus Full size table.

Table 3 Number of studies and cardiovascular outcomes reported, by country Full size table. Table 4 Summary of prevalence rates of cardiovascular comorbidities in persons with type 2 diabetes Full size table. Table 5 Mortality associated with cardiovascular disease in persons with type 2 diabetes Full size table.

Discussion In this systematic review of 4,, persons with T2DM, we estimated the overall prevalence of CVD at Age as a risk factor for CVD Age is a well-known risk factor for CVD.

Obesity as a risk factor for CVD Obesity has long been established as an independent risk factor for CVD [ 7 , 52 ], and is associated with CAD [ 53 , 54 ], atherosclerosis [ 51 ], and cardiac death [ 55 , 56 ].

CVD-related mortality in T2DM In persons with T2DM, CVD is responsible for at least half of the mortality, as previously mentioned. CVD prevalence rates across regions and countries As this was a global review, studies from across the world were included.

Limitations As with all literature reviews, we were limited by the availability of the literature and the validity and quality of the articles. Conclusions This is the first systematic review to synthesize global prevalence rates of CVD, including stroke, MI, angina, heart failure, atherosclerosis and CAD among people with T2DM.

References International Diabetes Federation. Google Scholar Abraham TM, Pencina KM, Pencina MJ, Fox CS. Article Google Scholar International Diabetes Federation. Google Scholar Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Angelantonio D, et al.

Article PubMed CAS Google Scholar Singh GM, Danaei G, Farzadfar F, Stevens GA, Woodward M, Wormser D, Kaptoge S, Whitlock G, Qiao Q, Lewington S.

Article PubMed PubMed Central CAS Google Scholar Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Article Google Scholar Van Hateren KJ, Landman GW, Kleefstra N, Logtenberg SJ, Groenier KH, Kamper AM, Houweling ST, Bilo HJ.

Article PubMed PubMed Central CAS Google Scholar The Diabetes Control and Complications Trial Research Group. Article Google Scholar Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B.

Article PubMed Google Scholar ADVANCE Collaborative Group. Article Google Scholar UK Prospective Diabetes Study. Article Google Scholar Action to Control Cardiovascular Risk in Diabetes Study.

Article Google Scholar Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned J, Hammes H-P, Huikuri H.

Article PubMed Google Scholar Schnell O, Rydén L, Standl E, Ceriello A. Article PubMed PubMed Central Google Scholar Food and Drug Administration: Guidance for industry: diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes.

Article PubMed CAS Google Scholar Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS. Article CAS Google Scholar Sanon VP, Patel S, Sanon S, Rodriguez R, Pham SV, Chilton R.

Article PubMed PubMed Central CAS Google Scholar Trujillo JM, Nuffer WA. Article PubMed PubMed Central Google Scholar Schnell O, Cappuccio F, Genovese S, Standl E, Valensi P, Ceriello A. Article PubMed PubMed Central CAS Google Scholar Ford ES, Zhao G, Li C. Article PubMed Google Scholar Saquib N, Saquib J, Ahmed T, Khanam MA, Cullen MR.

Article PubMed PubMed Central Google Scholar Moher D, Liberati A, Tetzlaff J, Altman DG. Article PubMed Google Scholar von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, Initiative S.

Article Google Scholar Bhatti GK, Bhadada SK, Vijayvergiya R, Mastana SS, Bhatti JS. Article Google Scholar Collier A, Ghosh S, Hair M, Waugh N.

Article CAS Google Scholar Tan ED, Davis WA, Davis TM. Article Google Scholar Shestakova M: Dynamics in prevalence of diabetes, diabetic complications and quality of diabetes care in Russian Federation in — by data of national diabetes register.

Article PubMed PubMed Central Google Scholar Cardoso C, Salles G. Article PubMed CAS Google Scholar Carnethon MR, Biggs ML, Barzilay J, Kuller LH, Mozaffarian D, Mukamal K, Smith NL, Siscovick D. Article PubMed PubMed Central Google Scholar Eeg-Olofsson K, Cederholm J, Nilsson PM, Zethelius B, Svensson AM, Gudbjörnsdóttir S, Eliasson B.

Article PubMed CAS Google Scholar Malik MO, Govan L, Petrie JR, Ghouri N, Leese G, Fischbacher C, Colhoun H, Philip S, Wild S, McCrimmon R, et al. Article PubMed CAS Google Scholar Salinero-Fort MA, Andres-Rebollo FJ, Burgos-Lunar C, Abanades-Herranz JC, Carrillo-de-Santa-Pau E, Chico-Moraleja RM, Jimenez-Garcia R, Lopez-de-Andres A, Gomez-Campelo P.

Article Google Scholar Menzaghi C, Xu M, Salvemini L, De Bonis C, Palladino G, Huang T, Copetti M, Zheng Y, Li Y, Fini G. Article PubMed PubMed Central CAS Google Scholar Tamba SM, Ewane ME, Bonny A, Muisi CN, Nana E, Ellong A, Mvogo CE, Mandengue SH.

Article Google Scholar Boonman-de Winter LJ, Rutten FH, Cramer MJ, Landman MJ, Liem AH, Rutten GE, Hoes AW. Article PubMed PubMed Central CAS Google Scholar Wentworth JM, Fourlanos S, Colman PG.

Article CAS Google Scholar Glogner S, Rosengren A, Olsson M, Gudbjörnsdottir S, Svensson AM, Lind M. Article CAS Google Scholar Alaboud AF, Tourkmani AM, Alharbi TJ, Alobikan AH, Abdelhay O, Al Batal SM, Alkashan HI, Mohammed UY.

Article PubMed PubMed Central Google Scholar Alonso-Moran E, Orueta JF, Fraile Esteban JI, Arteagoitia Axpe JM, Marques Gonzalez ML, Toro Polanco N, Ezkurra Loiola P, Gaztambide S, Nuno-Solinis R. Google Scholar Carrasco-Sánchez FJ, Gomez-Huelgas R, Formiga F, Conde-Martel A, Trullàs JC, Bettencourt P, Arévalo-Lorido JC, Pérez-Barquero MM.

Article PubMed Google Scholar Gregg EW, Cheng YJ, Saydah S, Cowie C, Garfield S, Geiss L, Barker L. Article Google Scholar Lin PJ, Cohen JT, Kent WA, Neumann PJ. Article Google Scholar Song S, Hardisty C. Article PubMed CAS Google Scholar Yang HK, Kang B, Lee S-H, Yoon K-H, Hwang B-H, Chang K, Han K, Kang G, Cho JH.

Article Google Scholar Mansour AA, Ajeel NA. Article Google Scholar Menghua Z. Article Google Scholar Norhammar A, Bodegard J, Nystrom T, Thuresson M, Eriksson JW, Nathanson D. Article PubMed CAS Google Scholar Rossi MC, Lucisano G, Comaschi M, Coscelli C, Cucinotta D, Di Blasi P, Bader G, Pellegrini F, Valentini U, Vespasiani G.

Article Google Scholar Hubert HB, Feinleib M, McNamara PM, Castelli WP. Article PubMed CAS Google Scholar Rabkin SW, Mathewson FA, Hsu PH. Article PubMed CAS Google Scholar Garcia-Labbe D, Ruka E, Bertrand OF, Voisine P, Costerousse O, Poirier P.

Article PubMed Google Scholar Plourde B, Sarrazin JF, Nault I, Poirier P. Article CAS Google Scholar Engeland A, Bjorge T, Sogaard AJ, Tverdal A.

Article PubMed Google Scholar Masmiquel L, Leiter L, Vidal J, Bain S, Petrie J, Franek E, Raz I, Comlekci A, Jacob S.

Article PubMed PubMed Central CAS Google Scholar World Health Organization. Google Scholar Gujral UP, Pradeepa R, Weber MB, Narayan KM, Mohan V. Article PubMed PubMed Central Google Scholar Raji A, Seely EW, Arky RA, Simonson DC.

Article PubMed CAS Google Scholar Huxley R, James W, Barzi F, Patel J, Lear S, Suriyawongpaisal P, Janus E, Caterson I, Zimmet P, Prabhakaran D. Article PubMed Google Scholar World Health Organization Expert Consultation. Article Google Scholar Koellhoffer EC, McCullough LD.

Article PubMed CAS Google Scholar Meseguer A, Puche C, Cabero A. Article PubMed CAS Google Scholar Hartrumpf M, Kuehnel RU, Albes JM. Article PubMed Google Scholar Lee KS, Moser DK, Lennie TA, Pelter MM, Nesbitt T, Southard JA, Dracup K. Article PubMed Google Scholar Abi Khalil C, Sulaiman K, Singh R, Jayyousi A, Asaad N, AlHabib KF, Alsheikh-Ali A, Al-Jarallah M, Bulbanat B, Al Mahmeed W, et al.

Google Scholar Straka RJ, Liu LZ, Girase PS, DeLorenzo A, Chapman RH. Article PubMed PubMed Central Google Scholar Senthil AN, Ravishankar G, Ravi MS, Meenakshi K, Muthu Kumar D, Swaminathan N, Paul J, Venkatesan S.

Article Google Scholar Nair M, Prabhakaran D. Article PubMed Google Scholar Azoulay L, Suissa S. Article CAS Google Scholar World Health Organization. Google Scholar Jung CH, Chung JO, Han K, Ko S-H, Ko KS, Park J-Y. Article PubMed PubMed Central Google Scholar Huang Y, Li J, Zhu X, Sun J, Ji L, Hu D, Pan C, Tan W, Jiang S, Tao X.

Article PubMed Google Scholar Simmons RK, Griffin SJ, Lauritzen T, Sandbæk A. Article PubMed PubMed Central Google Scholar Simmons RK, Griffin SJ, Witte DR, Borch-Johnsen K, Lauritzen T, Sandbæk A.

Article PubMed PubMed Central Google Scholar Kelsall HL, Fernando PHS, Gwini SM, Sim MR. Article PubMed Google Scholar Li M-F, Zhao C-C, Li T-T, Tu Y-F, Lu J-X, Zhang R, Chen M-Y, Bao Y-Q, Li L-X, Jia W-P.

Article PubMed PubMed Central Google Scholar Mohammedi K, Woodward M, Marre M, Colagiuri S, Cooper M, Harrap S, Mancia G, Poulter N, Williams B, Zoungas S.

Article PubMed PubMed Central Google Scholar Malik S, Zhao Y, Budoff M, Nasir K, Blumenthal RS, Bertoni AG, Wong ND.

Article PubMed PubMed Central Google Scholar Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Article PubMed CAS Google Scholar Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart J-C, Haffner S, Hsia J, Breazna A, LaRosa J, Grundy S.

Article CAS Google Scholar Stein EA, Lane M, Laskarzewski P. Article PubMed CAS Google Scholar Ren Y, Ren Q, Lu J, Guo X, Huo X, Ji L, Yang X. Article CAS Google Scholar Clua-Espuny JL, González-Henares MA, Queralt-Tomas MLL, et al.

Article PubMed PubMed Central CAS Google Scholar Cheng Y, Zhang H, Chen R, Yang F, Li W, Chen L, Lin S, Liang G, Cai D, Chen H.

Article PubMed PubMed Central CAS Google Scholar Cortez-Dias N, Martins S, Belo A, Fiuza M. PubMed Google Scholar Daghash MH, Bener A, Zirie M, Dabdoob W, Al-Hamaq AO, Al-Arabi ZA.

Article PubMed Google Scholar Doucet JA, Bauduceau B, Le Floch JP, Verny C. Article PubMed CAS Google Scholar Farrell C, Moran J. Google Scholar Fu AZ, Qiu Y, Radican L, Yin DD, Mavros P.

Article CAS Google Scholar Giallauria F, Fattirolli F, Tramarin R, Ambrosetti M, Griffo R, Riccio C, De Feo S, Piepoli MF, Vigorito C. Article Google Scholar Gobardhan SN, Dimitriu-Leen AC, van Rosendael AR, van Zwet EW, Roos CJ, Oemrawsingh PV, Kharagjitsingh AV, Jukema JW, Delgado V, Schalij MJ.

Article PubMed Google Scholar Gondim F, Caribé A, Vasconcelos KF, Segundo AD, Bandeira F. CAS Google Scholar Hermans MP, Bouenizabila E, Ahn SA, Rousseau MF.

Article CAS Google Scholar Hunt KJ, Kistner-Griffin E, Spruill I, Teklehaimanot AA, Garvey WT, Sale M, Fernandes J. Article PubMed PubMed Central CAS Google Scholar Jackson CA, Jones NR, Walker JJ, Fischbacher CM, Colhoun HM, Leese GP, Lindsay RS, McKnight JA, Morris AD, Petrie JR, et al.

Article PubMed PubMed Central CAS Google Scholar Jurado J, Ybarra J, Solanas P, Caula J, Gich I, Pou JM, Romeo JH. Article PubMed Google Scholar Kucharska-Newton AM, Couper DJ, Pankow JS, Prineas RJ, Rea TD, Sotoodehnia N, Chakravarti A, Folsom AR, Siscovick DS, Rosamond WD.

Article PubMed Google Scholar Kwon H, Lim J, Shin J, Son J, Lee S, Kim S, Yoo S. Google Scholar Liu X, Liu Y, Lv Y, Li C, Cui Z, Ma J.

Article PubMed PubMed Central Google Scholar Luo Y, Wang X, Wang Y, Wang C, Wang H, Wang D, Liu L, Jia Q, Liu G, Zhao X, et al. Article Google Scholar MacDonald MR, Petrie MC, Home PD, Komajda M, Jones NP, Beck-Nielsen H, Gomis R, Hanefeld M, Pocock SJ, Curtis PS, McMurray JJ.

Article Google Scholar Mazza A, Zamboni S, Rizzato E, Pessina AC, Tikhonoff V, Schiavon L, Casiglia E. Article PubMed CAS Google Scholar Mody R, Kalsekar I, Kavookjian J, Iyer S, Rajagopalan R, Pawar V. Article Google Scholar Mundet X, Cano F, Mata-Cases M, Roura P, Franch J, Birules M, Gimbert R, Llusa J, Cos X.

Article Google Scholar Narksawat K, Sujirarat D, Panket P. Google Scholar Penno G, Solini A, Zoppini G, Fondelli C, Trevisan R, Vedovato M, Cavalot F, Gruden G, Lamacchia O, Laviola L.

Get monthly science-based diabetes and heart-healthy tips in your inbox. Know Diabetes by Heart raises awareness that living with Type 2 diabetes increases risk for heart disease and stroke — and that people should talk with their doctor at their next appointment about ways to reduce risk.

Home Health Topics Diabetes Diabetes Complications and Risks Cardiovascular Disease and Diabetes. Play without Auto-Play Play Video Text. Why are people with diabetes at increased risk for CVD? High blood pressure hypertension High blood pressure is a major risk factor for heart disease and stroke.

Studies have shown a link between high blood pressure and insulin resistance. When patients have both HBP and diabetes, which is a common combination, their risk for CVD increases even more.

Abnormal cholesterol and high triglycerides Patients with diabetes often have unhealthy cholesterol levels including high LDL "bad" cholesterol, low HDL "good" cholesterol, and high triglycerides. This often occurs in patients with premature coronary heart disease.

It's also characteristic of a lipid disorder associated with insulin resistance called atherogenic dyslipidemia, or diabetic dyslipidemia in patients with diabetes. Learn more about cholesterol abnormalities as they relate to diabetes. Download Type 2 Diabetes and Cholesterol PDF.

Obesity Obesity is a major risk factor for CVD and has been strongly associated with insulin resistance. Weight loss can improve cardiovascular risk, decrease insulin concentration and increase insulin sensitivity.

Obesity and insulin resistance also have been associated with other risk factors, including high blood pressure. Lack of physical activity Physical inactivity is another modifiable risk factor for insulin resistance and CVD.

Exercising and losing weight can prevent or delay the onset of Type 2 diabetes, reduce blood pressure and help reduce the risk for heart attack and stroke. Any type of moderate-to vigorous physical activity is beneficial, such as sports, house work, gardening or work-related physical activity.

Poorly controlled blood sugar too high or out of normal range Diabetes can cause blood sugar to rise to dangerous levels. Medications may be needed to manage your blood sugar. Smoking Whether or not they have diabetes, smoking puts people at higher risk for heart disease and stroke.

Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management Carotid wave analysis in young adults with a history of adolescent anorexia nervosa: a case control study. Although initial data from RCTs of GLP-1 agonists supported a neutral effect on the risk of HF, a recent meta-analysis showed benefits of GLP-1 agonists in HF and diabetes [ 67 ]. Table 4 Cardiovascular benefits of GLP-1 agonists Full size table. CAS PubMed Google Scholar Slieker, R. The American College of Cardiology ACC and AHA have developed a risk stratification tool for primary prevention in patients with T2DM; the Risk Estimator Plus tool can be used to calculate ten-year atherosclerosis CVD risk and provide individualized advice for patients aged 40—79 years.
Cardiovascular Disease and Diabetes | American Heart Association Hartrumpf M, Kuehnel RU, Albes JM. Predictive models for cardiovascular and kidney outcomes in patients with type 2 diabetes: systematic review and meta-analyses. Wong View author publications. Prognostic impact of the ankle-brachial index on the development of micro- and macrovascular complications in individuals with type 2 diabetes: the Rio de Janeiro Type 2 Diabetes Cohort Study. Excess mortality among persons with type 2 diabetes. Cardiovascular disease is common among persons with diabetes because of factors other than hyperglycemia; therefore, further studies are needed to confirm this finding.
DEAR Cardiovascuoar CLINIC: I Hyperglycemia and cardiovascular disease 42 Glucagon biosynthesis recently was Hgperglycemia Hyperglycemia and cardiovascular disease diabetes. My doctor said Carrdiovascular could manage Muscle building high-intensity workouts condition with diet and exercise for now but suggested I follow up with a Hyperg,ycemia. As far as I know, my heart is fine. What is the connection between diabetes and heart health? ANSWER: The number of people worldwide with diabetes is rising. While many may not realize it, having diabetes comes with a higher risk for heart disease. Research has shown that people with Type 2 diabetes are up to four times more likely than the general population to die from cardiovascular causes.

Author: Vobei

0 thoughts on “Hyperglycemia and cardiovascular disease

Leave a comment

Yours email will be published. Important fields a marked *

Design by ThemesDNA.com